Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.

Q4 guidance included expanded metrics for 2025, such as mid to high single-digit sales growth and low double-digit EPS growth, compared to a more cautious outlook in Q3. Management also introduced a ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it ...

Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots ...

The transaction would allow Sanofi to solely focus on its more lucrative, drugs and vaccines business. The company's research-and-development spending increased 24% on-year in the last quarter in an ...

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...